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Abstract
Inter-assay variation of antibody based routine tests is hampering comparability of measure-
ment results for growth hormone (GH) between different laboratories and decision making in
clinical practice. Here it is demonstrated, that quantification of GH by isotope dilution mass
spectrometry (IDMS) constitutes a way to precise and reliable results which can be referred to
in evaluation of performance of commercial test kits. With the IDMS method developed, tryp-
tic cleavage products YSFLQNPQTSLCFSESIPTPSNR (T6) and LEDGSPR (T12) of GH are
quantified by LC/MS-MS using the isotopically labeled forms of the peptides as internal stan-
dards. The GH cleavage fragments are obtained by whole-serum tryptic proteolysis and then
extracted from the resulting mixture by semi-preparative reversed phase liquid chromatography
followed by strong cation-exchange chromatography. Method validation basing on recovery of
recombinant 22 kDa GH, spiked to blank serum in defined amounts covering the intended con-
centration range 3 µg/L to 30 µg/L, would yield mean recoveries of 101.6% (100.7%), standard
deviations (SD) of 2.5% (2.4%) and combined uncertainties (uc) of 3.0% (2.5%) if quantifying
T6 (T12) as GH derived fragments, while the LOQ were 1.7 µg/L (2.7 µg/L). Potential to
acquisition of reference values is exemplified by application to serum materials used in a recent
quality assessment exercise for routine laboratories.
Keywords: Growth hormone, GH, somatotropin, serum, quantification, standardization, reference
measurement, LC/MS-MS, isotope dilution mass spectrometry, IDMS.
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1 Introduction
Diagnosis of growth hormone (GH) deficiency and -excess (acromegaly) is based on determination of
circulating concentrations of GH in serum during dynamic tests [1, 2]. In spite of efforts to standard-
ization, decision making in clinical practice continues being hampered by significant discrepancies
in assay results between different laboratories (test methods). The variation is attributed mainly to
different specificities of the antibodies used, varying degree of recognition of GH-dimers, differences
in recovery of GH being associated with growth hormone binding protein (GHBP), as well as matrix
interferences in general [3]. While part of the sources, in order to be eliminated are requiring a more
explicit definition of the measurand (e.g. epitope/isoform to be targeted), material improvement
as to the analytical quality of results can be expected by just taking advantage of selectivity and
reliability attainable by isotope dilution mass spectrometry (IDMS).
With small molecular diagnostic markers, IDMS has been a well established reference measure-
ment principle for almost 40 years [4-6]. However, in spite of earlier model experiments to extend
the scope of the technique to proteins [7] it was not until recently that quantification by IDMS of
protein markers in body fluids for diagnostic purposes has been reported [8-13]. Measurement of GH
by MS has been discussed previously, namely in a feasibility study [14], a discussion of MS as fast
alternative method regarding the time needed for development of antibody based assays [15] and
with an investigation about optimal conditions for proteolysis of serum samples [16]. Neither of the
methods was applicable to measurement of samples in clinical practice at primary level, however,
since no use was made of isotopically labeled internal standards and concentration ranges considered
in these examples were far above what is relevant in clinical practice.
The present paper introduces an IDMS based quantification method which is applicable to sam-
ples with GH ranging from 3 µg/L to 30 (µg/L). Adopting a general strategy in quantitative pro-
teomics [17], tryptic cleavage products of GH are being quantified as signature fragments in place of
GH as a whole. This way, the measurand, (whole-) GH, is represented by the amount-of-substance
of the selected fragments. Labeled versions of these are added to the samples prior to proteolysis.
Sensitive detection of the targeted fragments is requiring effective separation from the complex pro-
teolysis product. This is achieved by clean-up using two-step chromatography. The potential of the
method to providing reference values is demonstrated with a set of sera which recently have been
used in an external quality assurance scheme for clinical testing laboratories [18].
Abbreviations: GH: growth hormone, GHBP: Growth hormone binding protein, IDMS: isotope dilution mass
spectrometry, LC: liquid chromatography, LC/MS-MS: liquid chromatography-tandem mass spectrometry, ESI: elec-
trospray- ionization, LOD: limit of detection, LOQ: limit of quantification, TFA: trifluoroacetic acid, RP: reversed
phase, SCX: strong cation exchange, SPE: solid phase extraction, MRM: multiple reaction monitoring, Q1, Q3:
quadrupole 1, quadrupole 3, SD: standard deviation, TPCK: L-1-Tosylamide-2-phenylethyl chloromethyl ketone.
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2 Materials and methods
Reagents and chemicals. Bovine trypsin (treated with L-1-Tosylamide-2-phenylethyl chloro-
methyl ketone, TPCK), TRISMA Hydrochloride, TRIS-base, iodoacetamide (IAA), dithiothreitol
(DTT), acetonitrile (CHROMASOLV grade) and trifluoroacetic acid (TFA) were from Sigma-Aldrich
(St. Louis, USA), acetic acid (BioChemika Ultra grade) from Sigma-Aldrich Chemie (Buchs, Switzer-
land). Formic acid (98-100%, p.a.), calcium chloride (CaCl2), and methanol (HPLC grade) were
obtained from Merck (Darmstadt, Germany). Recombinant 22 kDa GH (Swiss-Prot database
entry: P01241) was from ProSpec-Tany TechnoGene (Rehovot, Israel). Cleavage fragments YS-
FLQNPQTS(L)CFSESIPTPSNR (amino acids 42-64) and LEDGS(P)R (amino acids 128-134),
corresponding to tryptic peptides T6 and T12, had been obtained in labeled form from Thermo
Electron G.m.b.H. (Ulm, Germany), using leucine [13C6,
15N-] in position (L) of the sequence and
proline [13C5,
15N-] in position (P), respectively. For the purposes of this paper the labeled pep-
tides will be referred to as T6* and T12*. Recombinant human growth hormone soluble receptor
(growth hormone binding protein, GHBP) had been obtained from Protein Laboratories Rehovot
Ltd. (Jerusalem, Israel).
GH reference solution and solutions of labeled peptide internal standards. A (stock-)
reference solution of recombinant 22 kDa GH at 30.8 nmol/g (681 µg/g) in 1/1 (v/v), acetoni-
trile/water, was used for preparation of calibration solutions as well as for defined spiking of GH to
serum samples used for method validation. Stock solutions of T6* and T12* used for additions of
labeled internal standards were of 102.55 nmol/g and 146.81 nmol/g, respectively, in water. Con-
centrations of these solutions had been determined by amino acid analysis as described in a previous
paper [19].
Material used in method validation. Pooled human serum (NIST SRM(R) 971, female serum
subset [20]), was spiked with different amounts of GH to yield samples at (target-) concentrations
of 0, 5, 10, 20 and 30 µg/L. A working solution obtained from the GH reference solution by dilution
with acetonitrile/water, 1/1 (v/v), 0.1 M acetic acid, down to 22.12 pmol/g was used to this. Of
this solution, 0, 5, 10, 20 and 30 mg were added to 500 µL aliquots of the serum. Samples were
prepared in duplicate at each of the concentration levels resulting in eight GH-fortified samples to
be analysed. No GH had been detectable with the pure serum (i.e., without addition) using the
measurement protocol being described in this report.
Material used as example for method application. Samples from two serum pools (HP1/08
A and HP1/08 B), were obtained from DGKL, Referenzinstitut fu¨r Bioanalytik, D-53127 Bonn,
Germany [18]. These were pooled human sera fortified with pituitary GH extract. Prior to IDMS
analysis, the lyophilized material was reconstituted with 3 mL water per vial according to the
suppliers protocol.
Calibration solutions. Calibration solutions were prepared by adding defined amounts of GH,
T6* and T12* to 500 µL aliquots of water. The amounts to be added were chosen so as to mimic
the concentration of GH expected with the serum sample to be analysed. Additions were made from
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working solutions obtained by dilution to 22.12 pmol/g of the (stock-) GH reference solution and
the solutions of the labeled peptide internal standards.
Proteolysis. 500 µL of the sample (serum or calibration solution) were added to 12.1 mg TRIS
base, 15.8 mg TRIS-HCL and 2.2 mg CaCl2 (pH=8.2). To this, 50 µL of a solution containing
20 mg/mL trypsin in acetic acid (50 mM) were added and the sample was incubated at 37 ◦C. After
10, 30, 90, 150 and 210 min, respectively, another 50 µL aliquot of the trypsin solution was spiked
into the reaction vial. In parallel, 100 µL of acetonitrile were added every 30 minutes starting at
t=30 min, resulting in a final fraction of 58% acetonitrile after 330 min. The reaction was allowed
to proceed for a total of 24h (1440 min). Following reductive cleavage of cysteine links (3.2 mg
DTT, 1h at 37 ◦C) the non soluble fraction was removed by centrifugation (15 min at 17860 g).
The residue was extracted with 1 mL of acetonitrile/water, 1/1 (v/v), and the extract added to the
filtrate from centrifugation. This was lyophilized and re-dissolved in 400 µL water. Again, the non
soluble residue was removed by centrifugation (15 min at 3809 g) and the extract of the residue
(300 µL) was added to the filtrate. After alkylation (15.7 mg IAA, incubation for 30 min at room
temperature, then addition of 12.9 mg DTT) 15.3 µL TFA in 100 µL water were added.
Extraction of T6,T6* and T12,T12* by two-step liquid chromatography. T6,T6* and
T12,T12* were extracted using reversed-phase (RP) chromatography on a Jupiter 300 A˚ C18
column, 10×250 mm (Phenomenex, Torrance, CA), followed by strong cation exchange (SCX-)
chromatography (Luna 5 µm SCX 100 A˚, 10×250 mm, Phenomenex). An ELITE LaChrom LC
system (VWR-HITACHI, Darmstadt, Germany) consisting of a low pressure binary pump, autosam-
pler, column oven, VWD detector and a Foxy Jr. fraction collector (Teledyne ISCO, Lincoln, NE)
was used for separation and fraction collection. Of the proteolysis product, 5 times 170 µL were
injected onto the RP column which was run at 1.5 mL/min flow rate of the mobile phase. A solvent
gradient was applied of 100% A (0-5 min)→ 80% B (at 45-50 min)→100% A (at 50.5-90 min),
where A: water (0.1% TFA) and B: acetonitrile (0.1% TFA). Time windows for collection were
33.4-34.5 min (T6,T6*) and 25.2-26.2 min (T12,T12*). For SCX chromatography, the gradient was
100% C (0-3 min)→100% D (40-45 min)→ 100% C (45.1-90 min), where C: KH2PO4, 5 mM in
acetonitrile/water, 1/4, pH=2.83 and D: KH2PO4, 5 mM, plus KCl, 0.5 M in acetonitrile/water,
1/4, pH=2.83. Each collected fraction (one for T6,T6*, another one for T12,T12*) from RP chro-
matography was lyophilized and re-dissolved in 600 µL mobile phase C, prior to injecting the whole
amount (2×600 µL in two separate runs) onto the SCX column. Collection windows were 34.8-
36.5 min in the run with the T6,T6* containing fraction and 34.9-36.4 min with the T12,T12*
containing one. After SCX-chromatography the respective fractions were desalted according to a
standard protocol using SPE C18 ec cartridges (Chromabond, 500 mg, Macherey&Nagel, Du¨ren,
Germany). After lyophilization, residues were re-dissolved in 20 µL water (0.1% formic acid) before
analysis by LC/MS-MS.
Analysis by LC/MS-MS. Samples were analyzed on an Agilent 1100 series LC- instrument
(Agilent Technologies Deutschland G.m.b.H., Waldbronn, Germany) combined with a 4000 Q Trap
(Applied Biosystems, Foster City, CA) operated in ESI- (positive ion) mode. A Discovery BIO
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Figure 1: Amino acid sequence of 22 kDa GH (Swiss-Prot: P01241) and signature fragments (T6
and T12) chosen to represent the amount of GH.
wide pore C18 (2.1×150 mm, 3 µm, 300 A˚) RP- column was used at 200 µL/min flow rate of
mobile phase. The gradient applied was 100% A (0-3 min)→80% B (at 40-45 min)→ 100% A (at
45.1-60 min), where A: water (0.1% formic acid) and B: acetonitrile (0.1% formic acid). The whole
material as resulting from sample clean-up (2×20 µL) was injected in two separate analytical runs
(one with the T6,T6*-extract, another one with T12,T12*). The mass spectrometer was run in
MRM mode with Q1 and Q3 at unit resolution. Transitions monitored were m/z 892.3→671.3 and
m/z 894.6→671.3 for T6,T6* and m/z 387.4→531.3 and m/z 390.4→537.3 for T12,T12*, which
corresponds to [M+3H]3+ → y6 with T6,T6* and [M+2H]2+ → y5 with T12,T12*. Fragmentation
was induced using nitrogen at high pressure setting and at collision energies of 50 eV (T6,T6*)
and 20 eV (T12,T12*), respectively. The ESI source was operated at 5.5 kV sprayer voltage and
350 ◦C dry gas temperature. All other parameters had been optimized to obtain maximum signal
intensities for T6,T6* and T12,T12*, respectively. Under the conditions used, retention times were
24.0 min for T6,T6* and 14.1 min for T12,T12*.
Measuring substance- and signal recovery after extraction of T6,T6* and T12,T12*.
NIST SRM(R) 971 (female serum), same material as with validation experiments, was used as blank
matrix. T6* and T12* were utilized as markers. Solutions used for additions, contained 20.2 pmol/g
(T6*) and 20.6 pmol/g (T12*) in acetonitrile/water 1/1 (v/v), 0.1 M acetic acid. T6*(T12*) were
spiked to the blank serum at different stages of the clean-up/ extraction process and the LC/MS-
MS response was recorded each time. The amounts spiked were chosen such as to correspond to
10 µg/L 22 kDa GH. Substance recoveries were obtained by relating the signals observed with
spiking of T6*(T12*) prior to clean-up by two-step chromatography to those observed if spiking the
blank serum after it had been subjected to the same procedure. For obtaining signal recoveries, an
aqueous solution of T6*(T12*), same concentration as before, was used as reference instead. In a
second experiment, signal recovery was determined for a reduced clean-up procedure omitting the
SCX- chromatography step.
Testing for interference by presence of GHBP. T6* and T12* internal standard solutions
were spiked to a solution containing GHBP and GH in molar ratio 9:1. The final volume was
500 µL and concentrations were 5.0/0.54/0.55/0.56 nmol/L (GHBP/GH/T6*/T12*). The mixture
was incubated at 4 ◦C overnight and analyzed immediately after. For comparison, another sample
was prepared in the same way, just missing out addition of GHBP.
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3 Results
Choice of GH-specific fragments. The cleavage fragments of GH used for quantification (T6
and T12) are shown in Fig. 1. They were selected so as to selectively code for GH in complex
matrix. BLAST search (BLASTP 2.2.21 database) and MS-Homology (UCSF Protein Prospector)
were used for alignment and identification of potentially interfering cleavage products from other
proteins. With T6, sequence alignment yielded exact matches exclusively with GH whereas in the
case of T12 a second hit (caspase recruitment domain protein 9, isoform 2) additionally is returned.
In this protein, the T12 sequence is flanked by amino acids other than lysine and arginine, however,
and trypsin does not release T12 as a fragment from it. Apart from about 1% glycosylation in
the sequence range covered by T6, no posttranslational modifications are observed with GH in the
regions of T6 and T12 [21], so the mass spectrometric signals monitored virtually correspond to all
of T6 and T12 present after proteolysis.
Method. The workflow of the method developed is shown in Fig. 2. With each sample, a
separate calibration solution is used as prepared by appropriate dilution from the (stock-) GH
reference solution. The concentration is chosen in a range as close as possible to what is expected
in the serum samples to be analyzed (which may require a preliminary analysis run for orientation).
GH-specific signature fragments (here: T6 and T12) are spiked as internal standards in isotopically
labeled form (denoted as T6* and T12*) in equal amounts to both, serum sample and calibration
solution. Exact matching [22] the analyte concentration of the sample with the calibration solution is
on purpose to eliminate systematic errors that otherwise would result from uncertainty in knowledge
of the degree of isotopic enrichment in the labeled internal standard used [23]. In order to ensure
complete release of T6 and T12 from GH, sample and calibration solution are incubated for 24h
at 37 ◦C in presence of 20 mg/L trypsin (water/acetonitrile, 2/3, v/v). Semi-preparative reversed
phase liquid chromatography (RP-LC) followed by strong-cation-exchange (SCX) chromatography
is used to separate the target peptides from the proteolysis product prior to analysis of signal ratios
T6/T6* and T12/T12* by analytical scale RP-LC/MS-MS on a triple-quadrupole instrument. The
amount of GH (two separate results: one using T6, another one for T12), is calculated based on
comparison of the signal ratios obtained for that fragment in the sample and in the calibration
solution, which corresponds to comparison of the amount of fragment generated from GH in the
sample to the known amount generated from the calibration solution, since equal amounts of labeled
internal standard had been spiked with both. The detailed protocols for proteolysis, extraction of
T6,T6* and T12,T12* as well as analysis by mass spectrometry are provided in the corresponding
subsections of Materials and Methods. Ion chromatograms from LC/MS-MS as obtained for a serum
sample are shown in Fig. 3.
Substance- and signal recovery of the signature fragments. Substance recoveries after
extraction of T6,T6* and T12,T12* by two-step chromatography, as described, were found to be
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Figure 2: Workflow of the method for quantification of GH by isotope dilution mass spectrometry
(IDMS). Tryptic cleavage fragments of GH (T6 and T12) are quantified using 22 kDa GH as reference
substance of known concentration and the isotopically labeled analogues (T6* and T12*) as internal
standards. Isolation of T6,T6* and T12,T12* from samples prior to measurement by LC/MS-MS is
done by a two-step procedure consisting of semi preparative reversed phase liquid chromatography
(RPLC) followed by strong cation-exchange (SCX) chromatography.
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Figure 3: Instrumental responses obtained for GH signature fragments (T6, T12), black graphs,
compared to those of the labeled internal standards (T6*,T12*), red, in analysis of quality con-
trol serum HP1/08 B. The ion chromatograms shown were monitored for analyte-specific MS-MS
transitions. (A) T6-based quantification. (B) T12-based quantification.
61% with T6,T6* and 64% with T12,T12*. At the same time, signal recoveries were 14% (8%).
Curtailing the clean-up procedure by leaving out the SCX-chromatography step would result in a
decrease of signal recoveries to 3% (1%).
Validation. Method performance was characterized based on evaluation of analytical recovery
of defined amounts of GH spiked to a serum material which had been checked not to contain GH at a
concentration detectable with the present method. Recombinant 22 kDa GH-reference solution was
used for the additions, which previously [19] had been value-assigned by IDMS-based amino acid
analysis. Eight samples were prepared at four different concentration levels ranging 4.5-30.5 µg/L.
All samples were analyzed completely independent of one another on different occasions (days)
using a separate calibration solution freshly prepared from the GH reference solution alongside
each sample. Therefore, the observed deviation from the respective target value for each individual
sample is containing all random errors occurring in sample treatment and instrumental analysis,
including those between different days. Quantification results are compiled in Table 1. Plots of
results by T6 (T12) vs. expected GH concentrations (not shown) are of excellent linearity. In
particular, R2 = 0.999 (0.999), sy·x = 0.22 (0.34), slope a = 1.04 (0.99), intercept b = −0.21 (0.10)
were obtained by regression analysis. LOD calculated from the data using the linear-regression
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GH concentration µg/L Recovery %
by T6 by T12 expected by T6 by T12
4.79 4.82 4.63 103.5 104.1
4.45 4.60 4.58 97.2 100.4
10.24 10.49 10.19 100.5 102.9
10.14 10.15 10.25 98.9 99.0
20.28 19.99 19.51 103.9 102.5
19.71 18.70 19.32 102.0 96.8
30.57 29.17 29.39 104.0 99.3
31.24 30.43 30.31 103.1 100.4
Mean recovery (%) 101.6 100.7
Mean bias (%) 1.6 0.7
SD (%) 2.5 2.4
uc (%) 3.0 2.5
Table 1: Recovery of GH added to blank serum and method performance data derived from this.
approach [24] was 0.5 µg/L (0.7 µg/L) and LOQ=1.7 µg/L (2.7 µg/L). Combination of mean bias,
though not significant, and standard deviation (Table 1) is resulting in estimates of 3.0% (2.5%) as
combined standard uncertainty (uc) [25] attributable to the IDMS method.
Test for interference by GHBP. Effect of presence of GHBP on quantification results was in-
vestigated in a separate model experiment. Two solutions were processed according to the described
protocol. Both were containing GH at 11.9 µg/L as well as T6* and T12* as internal standards. One
of them additionally had been spiked with GHBP in 9-fold molar excess. There was no significant
difference in signal ratios found in presence of GHBP and without: 1.00 (1.00) for T6/T6* and 0.91
(0.92) for T12/T12*.
IDMS measurement of GH in quality control materials. Samples from two serum
pools, HP1/08 A and B, which recently had been used as test materials in an external quality
assessment scheme [18] were re-analyzed by IDMS. Results were 7.07 (6.81) µg/L for pool A and
12.33 (12.28) µg/L for pool B with T6- (T12-) based quantification (means of n=3 runs, each). The
data reported by 174 testing laboratories are visualized as Youden plots in Fig. 4(a-f). For reference,
the IDMS results are included.
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Figure 4: IDMS results obtained for GH in comparison to those reported by testing laboratories in
an external quality assessment exercise. Red circle: T6-based result, red triangle: T12 based result.
All panels contain the same data, results by different test kits (manufacturers) being highlighted
with each one: (a) Siemens Medical Solutions (DPC/Biermann), (b) DiaSorin (c) Schering (CIS
Diagn.), (d) Mediagnost, (e) DSL, (f) PerkinElmer/Wallac (Delfia).
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4 Discussion
GH as found in vivo is displaying considerable heterogeneity. It has been described to consist
of several isoforms and variants resulting from modification of amino acid side chains, as well as
forming dimers and even aggregates of higher order [21, 26]. Clear definition of the measurand,
though vital with respect to comparability of measurements, is still subject to ongoing discussion in
clinical chemistry. The present report is demonstrating the performance of IDMS as an analytical
tool, given defined signature fragment(s) that are agreed upon to represent that measurand. Note,
that specification of a cleavage fragment in many situations is similar to selecting an epitope on
the surface of the protein. It may be anticipated therefore, that IDMS results correlate with those
of antibody-based measurements depending on which epitope is being recognized by the antibody.
In this study, T6 and T12 were selected as examples. They are both present on 22 kDa GH, the
most abundant isoform, as shown in Fig. 1. Suitability of the two fragments to represent GH is
further supported by the fact that virtually no posttranslational modification needs to be taken
into account, so the mass spectrometric signals monitored should collect virtually all of T6,T6* and
T12,T12* present after proteolysis.
The IDMS method reported is applicable to T6- (T12-) based serum measurement of GH in
clinically relevant concentration. By measurement principle, IDMS has the potential to provide
unbiased and reliable results at primary level of traceability to the SI [27]. This is supported by
the performance data given in Table 1. Standard deviations (2.5% and 2.4%, resp.) are as low as
customarily attained in quantitative LC/MS, and, bias appears not to be significant (SD>mean bias
in both cases, T6 and T12). Combining both components (repeatability and formally calculated
bias), the uncertainties would be about 3% and making allowance for another 3% uncertainty in
value assignment to the calibration material used, an overall estimate of uc ≈ 5% may be considered
reasonable for the type of measurement.
Measurement of GH, since present in serum only at trace concentration level takes particular
care in sample preparation so as to obtain instrumental responses of abundances enabling precise
quantification. Owing to suppression of analyte signals by competition with matrix ions present at
the same time [28] effective sample clean-up prior to measurement is crucial for quantification by ESI-
MS. Extraction of the proteolytic fragments from the sample by specific antibodies [8, 9, 29, 30] is a
promising approach to this. However, with the present method a chromatography-based alternative
is used which seems to be quite as efficient while curtailing time and expense for production of
antibodies. Performance data, in particular the limit of quantification (LOQ<3 µg/L) are at least
as good as what has been reported with antibody-based clean-up.
Using two-step chromatography (RP-LC plus SCX-) as described, signal recoveries were about
14% (8%) of what would have been obtained in complete absence of matrix-derived ions. Substance
recoveries, at the same time, are 61% (64%). The effect of matrix suppression can be roughly
estimated to be a factor 4-8 therefore, even after clean-up. Basically, improvement in substance
recovery would be expected if leaving out one of the chromatography steps. However, the gain in
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substance recovery is outweighed by the accompanying increase in matrix suppression, as becomes
manifest from the drop in signal recovery down to 3% (1%) if reducing analyte extraction to just
RP-LC. Obviously, both steps are required for the procedure to achieve the reported performance
(Table 1) and, in particular the LOD.
Interference by growth hormone binding protein, GHBP, as well as formation of GH-GH com-
plexes are considered significant sources for disagreement of results between different immunoassays.
No such interference is expected to occur if applying fragment based quantification, as done here,
unless proteolysis be obstructed by complex formation. However, this is not the case, as demon-
strated with the GHBP interference test which yielded the same result in presence of GHBP as in
absence. The IDMS method is capable of providing a measure of ’total’ GH, obviously.
Considering the results obtained by the testing laboratories for the samples investigated in the
external quality assurance exercise (Fig. 4) need for improvement is becoming evident. In both
cases, pool A and pool B, significant part of the whole range in which GH concentrations are
observed in clinical practice is covered by the spread of data. This would make clinical decision
very difficult without reference to method dependent cut-off values, if these were real patient sera.
Referring to the results by IDMS the most striking discrepancy is the one to the values obtained by
laboratories that were using the Siemens assay (Fig. 4a). A good deal of this presumably is caused
by lack of SI-traceability of the measurement: Many of these laboratories appear either not to have
calibrated against the recommended international standard (WHO IS 98/574), which has been SI
traceably value assigned [31], or wrong factors have been used in converting mU/L to the required
unit (µg/L). Apart from improper calibration, interferences by complex formation and recognition
of non representative epitopes by the antibodies used cross selectivity towards non target antigens
is among the potential causes for the deviations observed. In this situation, by the outstanding
selectivity of MS if compared to the detection principles used with immunochemical tests, combined
with reliability of IDMS in providing precise and SI-traceable results, the described method has the
potential to produce target values for the routine assays which eventually might be considered for
re-calibration of their results. In the present example, the DiaSorin (Fig. 4b) test seems to be best
in agreement with what is obtained by IDMS.
Though sufficient for GH quantification in materials presently used in quality control schemes and
also in clinical samples seen during stimulation tests, improvement of the LOQ by about one order
of magnitude would be required to extend the applicability to measure samples in patients during
glucose suppression tests, where GH concentrations less than 1 µg/L are expected [32]. In terms
of signal recovery, gaining a factor of 4-8 might be expected through complete elimination of ion
suppression effects by further improvement of the clean-up procedure. However, a more promising
option would consist of targeted enhancement of the analyte signals by appropriate conjugation of
amino acid side chains so as to increase their basicity. For instance, a 6-fold increase in response
factors has been reported on modifying cysteines with quaternary ammonium compounds [33].
Increase of method sensitivity to enable application to samples from suppression tests appears to
be possible therefore too.
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5 Conclusion
The results reported are demonstrating that, by using IDMS the road is paved to acquisition of
reference values for GH in serum at primary level of precision and reliability which are expected to
be reproducible not just between different laboratories but also if another GH reference preparation
should be used for calibration. The type of measurement is rendering a powerful tool for providing
backup to antibody based measurements.
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